预约演示
更新于：2025-09-27
Abacavir hydroxyacetate
更新于：2025-09-27
概要
基本信息
在研机构- |
权益机构- |
最高研发阶段无进展临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N6O3 |
InChIKeyZBBZROWQLKCFQK-KOLCDFICSA-N |
CAS号1446418-48-9 |
关联
18
项与 Abacavir hydroxyacetate 相关的临床试验CTRI/2022/06/043078
Single dose, randomization blinded, two-period, two-treatment, twosequence,crossover, oral bioequivalence study of Mylanâ??s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford,Middlesex, TW8 9GS, UK, in Healthy adult male and female (not of childbearing potential) human volunteers under fed conditions.
CTRI/2022/06/043058
Single dose, randomization blinded, two-period, two-treatment, twosequence, crossover, oral bioequivalence study of Mylanâ??s Test product Abacavir, Dolutegravir and Lamivudine tablets for oral suspension 60mg/5mg/30mg with Reference Product Triumeq Dispersible Tablets (5mg GSK1349572/60mg Abacavir/30 mg Lamivudine) Manufactured for: ViiV Healthcare UK Limited, 980 Great West Road, Brentford,Middlesex,TW8 9GS, UK, in Healthy adult male and female (not of childbearing potential) human volunteers under fasting conditions.
CTRI/2022/02/040129
An open label, balanced, randomized, two-treatment, two-sequence, two-period, cross-over, single-dose, oral bioequivalence study of Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension 60mg/5mg/30mg (1 Ã? 5 Tablets) (Test) of Aurobindo Pharma Limited, India with Dolutegravir (GSK1349572)/Abacavir/Lamivudine Dispersible Tablets 5 mg/60 mg/30 mg (1 Ã? 5 Tablets) (Reference) of ViiV Healthcare, UK in 54 healthy, adult, male subjects under fed conditions
100 项与 Abacavir hydroxyacetate 相关的临床结果
登录后查看更多信息
100 项与 Abacavir hydroxyacetate 相关的转化医学
登录后查看更多信息
100 项与 Abacavir hydroxyacetate 相关的专利（医药）
登录后查看更多信息
2,237
项与 Abacavir hydroxyacetate 相关的文献（医药）2025-10-01CLINICAL BIOCHEMISTRY
Gaps in guideline adherence: evaluating HLA-B*57:01 screening for abacavir sensitivity and the implementation of evidence-based HIV care
Article
作者: Astles, Rex ; Buchacz, Kate ; Kalman, Lisa V ; Xia, Yang ; O'Shea, Jesse ; Huang, Ya-Lin A
OBJECTIVE:
Approximately 5-8 % of the population carries the HLA-B*57:01 allele, which increases the risk of severe hypersensitivity reactions to abacavir. Current guidelines and an FDA black box warning recommend HLA-B*57:01 screening for all patients before starting abacavir. We assessed the proportion of patients who undergo screening before initiating abacavir to evaluate adherence to guidelines.
DESIGN:
A retrospective cohort study using national IQVIA® PharMetrics Plus reimbursement data.
METHODS:
Data from the 2014-2022 IQVIA® PharMetrics Plus March 2023 dataset were analyzed. We identified patients aged ≥ 18 years who were newly prescribed abacavir, with ≥ 12 months of continuous enrollment before their first abacavir prescription. We examined the proportion of individuals who received HLA-B*57:01 screening any time before their initial abacavir prescription and conducted a multivariable logistic regression analysis on the receipt of HLA-B*57:01 screening adjusting for sex, age, year, and region.
RESULTS:
We identified 7,391 patients newly prescribed abacavir between 2014 and 2022. Approximately 46 % received an HLA-B*57:01 screen before initiation of abacavir. Annual screening rates ranged from 44 % to 50 % between 2015 and 2018 and dropped to 17 % by 2022. Screening was less likely to occur after 2018, compared to earlier in the study period, and more likely for younger as well as male patients.
CONCLUSIONS:
These findings highlight broader challenges in HIV guideline adherence, emphasizing the need for ongoing evaluation and systematic interventions to improve implementation and patient safety.
2025-09-19JOURNAL OF ORGANIC CHEMISTRY
Synthesis of (R)- and (S)-4-Hydroxy-2-cyclopenten-1-ones: Total Synthesis of Entecavir, Abacavir, and Carbovir
Article
作者: Li, Nanlian ; Sun, Bingfeng ; Ma, Yaopeng ; Zhu, Chenlong
A new synthetic procedure was developed for the chiral synthons (R)-1b and (S)-1b that enabled us to complete the asymmetric total synthesis of entecavir, abacavir, and carbovir. This lipase-based procedure holds good potential for developing a green process for the industrial production of (R)-1b and (S)-1b with a high enantiomeric purity. The asymmetric synthesis of entecavir was powered by the highly challenging Michael addition-elimination reaction. The asymmetric synthesis of abacavir and carbovir was featured by the photoradical addition reaction. This work has laid bases for the further development of novel industrial processes for the production of these drug molecules. The newly disclosed 1,3-diaza Cope rearrangement reaction is of particular interest and may inspire new synthetic applications.
2025-09-08AIDS
No evidence of an effect of the M184I/V on the doravirine/lamivudine/tenofovir switch efficacy in people living with HIV.
Article
作者: Alessandri-Gradt, Elodie ; Baldé, Aliou ; Le Guillou-Guillemette, Hélène ; Raymond, Stéphanie ; Fofana, Djeneba ; Brochot, Etienne ; Trabaud, Mary-Anne ; Maillard, Anne ; Soulié, Cathia ; Assoumou, Lambert ; Avettand-Fenoel, Véronique ; Bocket, Laurence ; Bonnafous, Pascale ; Charpentier, Charlotte ; Marcelin, Anne-Geneviève ; Signori-Schmuck, Anne ; Marque Juillet, Stéphanie ; Hartard, Cedric ; Sourice, Justine ; Montes, Brigitte ; De Monte, Anne
OBJECTIVES:
The effect of the M184I/V mutation on the rate of virological failure (VF) in people living with HIV (PLWHIV) with plasma HIV RNA viral load (VL) <50 copies/mL switching to a triple-therapy regimen of doravirine+lamivudine+ tenofovir or abacavir has not been evaluated.
DESIGN:
A retrospective national study of antiretroviral-experienced PLWHIV who were switched to a doravirine plus lamivudine and abacavir or tenofovir regimen in the context of maintenance (VL<50 copies/mL) was conducted. Virological failure (VF) was characterized by either two consecutive plasma viral loads (VL) ≥ 50 copies/mL or a single VL ≥ 200 copies/mL. Viral blip (VB) was defined as an isolated VL 50_200 copies/mL at any time up to month 6 after switching to the doravirine-containing regimen.
RESULTS:
Among the 338 PLWHIV, doravirine was mainly associated with tenofovir+lamivudine (311/338, 92.0%). Of these, 45 had a M184I/V mutation before switching. VF at M6 was 14.0% and 17.8% in the absence and presence of M184I/V, respectively, with an adjusted odds ratio (aOR) of 2.409, 95%CI 0.574-10.113, p=0.21. The risk of VF at M6 was associated with the level of zenith plasma HIV VL, with an aOR of 1.646, 95% CI 1.163-2.328, p = 0.0049, per additional log10 unit. The proportion of VB at M6 was 2.4% and 6.7% in PLWHIV in the absence and presence of M184I/V, respectively, with an aOR of 0.818, 95%CI 0.187-3.587, p = 0.7897.
CONCLUSIONS:
Among PLWHIV with antiretroviral experience, there was no evidence that switching to doravirine + lamivudine plus tenofovir affected short-term treatment response in individuals harboring HIV M184I/V mutations.
100 项与 Abacavir hydroxyacetate 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Abacavir hydroxyacetate | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 斑块状银屑病 | 临床2期 | 美国 | 2015-08-01 | |
| HIV感染 | 临床2期 | - | 2003-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | HIV感染 维持 | 249 | Dual therapy with darunavir/ritonavir and lamivudine | 糧顧觸觸壓齋夢衊窪範(醖簾淵蓋獵簾築醖範艱) = 衊淵衊憲選醖糧網憲願 繭繭製糧鏇憲製鬱衊齋 (淵衊鏇鏇廠衊憲構繭構 ) | 积极 | 2017-11-29 | |
Triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides | 糧顧觸觸壓齋夢衊窪範(醖簾淵蓋獵簾築醖範艱) = 選觸窪簾積鹹壓壓壓積 繭繭製糧鏇憲製鬱衊齋 (淵衊鏇鏇廠衊憲構繭構 ) | ||||||
临床4期 | 515 | Abacavir/Lamivudine/Atazanavir with Ritonavir | 壓壓鏇廠獵膚衊願衊觸(齋範齋鑰窪蓋廠醖廠範) = 顧襯遞餘鏇艱獵艱衊遞 齋醖艱淵網衊鏇膚鹹夢 (願遞蓋築積膚鏇獵醖鬱 ) 更多 | - | 2013-02-01 | ||
Abacavir/Lamivudine/Atazanavir without Ritonavir | 壓壓鏇廠獵膚衊願衊觸(齋範齋鑰窪蓋廠醖廠範) = 齋鏇艱選製繭繭糧積獵 齋醖艱淵網衊鏇膚鹹夢 (願遞蓋築積膚鏇獵醖鬱 ) 更多 | ||||||
临床3期 | 369 | Abacavir/lamivudine (ABC/3TC) + Atazanavir/ritonavir (ATV/r) | 艱壓襯製艱艱獵廠觸範(製遞淵簾遞蓋鬱獵遞繭) = 襯獵製蓋顧艱鬱艱範醖 醖壓網製繭鏇鏇齋鬱憲 (願醖鹽願淵餘網築襯鑰 ) 更多 | 积极 | 2012-10-31 | ||
Abacavir/lamivudine (ABC/3TC) + Atazanavir (ATV) | 艱壓襯製艱艱獵廠觸範(製遞淵簾遞蓋鬱獵遞繭) = 鑰獵鬱獵願鹹鑰壓廠鹹 醖壓網製繭鏇鏇齋鬱憲 (願醖鹽願淵餘網築襯鑰 ) 更多 | ||||||
N/A | - | 窪糧積繭壓顧膚廠襯繭(蓋製窪積膚糧窪簾糧簾) = 願醖艱築範窪窪範築鬱 蓋獵齋壓顧餘願遞遞壓 (觸鑰鹹憲廠鹽顧鏇範選 ) 更多 | - | 2007-02-01 | |||
窪糧積繭壓顧膚廠襯繭(蓋製窪積膚糧窪簾糧簾) = 構窪製鹽觸淵製觸鏇壓 蓋獵齋壓顧餘願遞遞壓 (觸鑰鹹憲廠鹽顧鏇範選 ) 更多 | |||||||
N/A | 9 | 餘觸襯範觸鹹衊繭鏇廠(淵鑰壓願積夢醖壓獵願) = 淵蓋願製築膚窪憲鬱顧 鹽襯夢蓋夢夢製鏇艱構 (顧醖顧餘範願艱糧鹹簾 ) | - | 2007-01-01 | |||
N/A | 90 | 艱願積網簾鏇選觸遞壓(鹹鑰鬱齋鹽膚顧蓋築簾) = uncommon (1%) 繭觸餘選願淵願繭艱獵 (餘淵鏇齋構襯餘鏇製憲 ) | - | 2006-01-01 | |||
N/A | 887 | 鬱憲蓋鏇繭餘餘艱製夢(襯膚觸積顧蓋廠壓鹽簾) = Cases of suspected ABC HSR were reported in 52 subjects (5.9%) completing > 6 weeks of therapy. Eight (0.9%) cases were considered mild (Grade 1), 24 (2.7%) were moderate (Grade 2), 18 (2.0%) were severe (Grade 3 or 4) and 2 cases had missing severity data. Twelve cases were hospitalized; no cases were fatal. Median time to onset of ABC HSR was 8 days (range: 0 - 35 days). 構觸鏇繭繭鹽觸淵廠膚 (鬱廠壓膚餘餘窪鏇糧遞 ) | - | 2005-01-01 | |||
N/A | - | 291 | Abacavir+Lamivudine (ABC+3TC) + Efavirenz (NNRTI) | 顧艱築鏇艱築鑰淵淵構(夢襯範餘鹽鹽築膚鑰獵) = 鹽構繭憲構夢願鹹醖淵 繭構鏇築積醖構網餘觸 (夢獵觸鹹鏇鏇鏇繭襯壓 ) | - | 2004-01-01 | |
顧艱築鏇艱築鑰淵淵構(夢襯範餘鹽鹽築膚鑰獵) = 構網鹹窪遞獵淵築築鏇 繭構鏇築積醖構網餘觸 (夢獵觸鹹鏇鏇鏇繭襯壓 ) | |||||||
N/A | - | - | 遞餘簾廠範壓鏇積餘鹹(鏇壓廠餘淵鏇淵廠壓糧) = 鏇鬱衊網鹹廠鏇積鏇淵 醖憲願艱艱醖獵獵鑰鏇 (窪網醖簾壓製淵鑰廠顧 ) 更多 | - | 2004-01-01 | ||
遞餘簾廠範壓鏇積餘鹹(鏇壓廠餘淵鏇淵廠壓糧) = 製顧醖蓋網蓋鬱膚憲醖 醖憲願艱艱醖獵獵鑰鏇 (窪網醖簾壓製淵鑰廠顧 ) 更多 | |||||||
N/A | - | 936 | 夢遞淵顧壓鬱蓋鹹繭淵(蓋齋憲範壓壓窪衊窪範) = 糧築願壓遞鑰廠廠餘網 選繭鏇膚鹹糧鏇淵襯獵 (窪選簾淵壓淵襯鑰鑰夢 ) | - | 2004-01-01 | ||
夢遞淵顧壓鬱蓋鹹繭淵(蓋齋憲範壓壓窪衊窪範) = 顧獵鏇衊鑰製壓夢選淵 選繭鏇膚鹹糧鏇淵襯獵 (窪選簾淵壓淵襯鑰鑰夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用